NASDAQ:DVAX - Nasdaq - US2681582019 - Common Stock - Currency: USD
Taking everything into account, DVAX scores 5 out of 10 in our fundamental rating. DVAX was compared to 555 industry peers in the Biotechnology industry. Both the profitability and the financial health of DVAX get a neutral evaluation. Nothing too spectacular is happening here. DVAX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -6.35% | ||
ROE | -11.31% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 82.27% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.49 | ||
Debt/FCF | 4.82 | ||
Altman-Z | 1.47 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 11.93 | ||
Quick Ratio | 10.84 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 38.69 | ||
Fwd PE | 18.56 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 22.36 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
10.06
+0.14 (+1.41%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 38.69 | ||
Fwd PE | 18.56 | ||
P/S | 4.1 | ||
P/FCF | 22.36 | ||
P/OCF | 19.01 | ||
P/B | 2.28 | ||
P/tB | 2.28 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -6.35% | ||
ROE | -11.31% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 82.27% | ||
FCFM | 18.34% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.49 | ||
Debt/FCF | 4.82 | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 117.09% | ||
Cap/Sales | 3.24% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 11.93 | ||
Quick Ratio | 10.84 | ||
Altman-Z | 1.47 |